Skip to content

Sanofi, Glaxo finalize deal in Europe to supply 300M doses of COVID-19 vaccine

September 18, 2020

Following up on their earlier announcement, Sanofi (NASDAQ:SNY) and collaboration partner GlaxoSmithKline (NYSE:GSK) have inked an agreement with the European Commission to supply up to 300M doses of their COVID-19 vaccine after approval.

The EU will provide upfront funding to support the scale-up of manufacturing capacity in Europe. The antigen and final vaccine doses will be made at sites in Belgium, Italy, Germany and France.

A Phase 3 clinical trial should launch by year-end. If all goes according to plan, a regulatory application will be submitted in H1 2021.

The companies, which have also inked supply deals in the U.S. and UK, aim to produce up to 1B doses per year.

From → Uncategorized

Leave a Comment

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: